# A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

> **NCT03693508** · PHASE4 · COMPLETED · sponsor: **Fundacion SEIMC-GESIDA** · enrollment: 50 (actual)

## Conditions studied

- HIV Infections
- Severe Immunosuppression

## Interventions

- **DRUG:** Genvoya®

## Key facts

- **NCT ID:** NCT03693508
- **Lead sponsor:** Fundacion SEIMC-GESIDA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-13
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-05-28
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693508, "A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03693508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*